Genetic modifiers for neuromuscular diseases

Journal of Neuromuscular Diseases

Volumn 1, Issue 1, 2014, Pages 3-13

  Lamar, Kay Marie ^a   McNally, Elizabeth M ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Amyotrophic lateral sclerosis; Genetic modifier; Muscular dystrophy; Spinal muscular atrophy

Indexed keywords

CALPHOBINDIN II; EPHRIN RECEPTOR A4; OSTEOPONTIN; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2;

AMYOTROPHIC LATERAL SCLEROSIS; ANXA6 GENE; EPHA4 GENE; GENE EXPRESSION PROFILING; GENETIC VARIATION; GENOME-WIDE ASSOCIATION STUDY; HUMAN; LTBP4 GENE; MODIFIER GENE; MUSCULAR DYSTROPHY; NEUROMUSCULAR DISEASE; NONHUMAN; PLS3 GENE; PRIORITY JOURNAL; QUANTITATIVE TRAIT LOCUS MAPPING; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; SMN GENE; SMN2 GENE; SPINAL MUSCULAR ATROPHY; SPP1 GENE; ZPR1 GENE;

EID: 84922507786     PISSN: 22143599     EISSN: 22143602     Source Type: Journal    
DOI: 10.3233/JND-140023     Document Type: Review

References (89)

1. Van Hoecke, A., Schoonaert, L., Lemmens, R., Timmers, M., Staats, K. A., Laird, A. S., Peeters, E., Philips, T., Goris, A., Dubois, B., Andersen, P. M., Al-Chalabi, A., Thijs, V., Turnley, A. M., van Vught, P. W., Veldink, J. H., Hardiman, O., Van Den Bosch, L., Gonzalez-Perez, P., Van Damme, P., Brown, R. H., Jr., van den Berg, L. H., and Robberecht, W. EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans. Nat Med. 2012; 18(9): 1418-1422.
2. Turner, B. J., Alfazema, N., Sheean, R. K., Sleigh, J. N., Davies, K. E., Horne, M. K., and Talbot, K. Overexpression of survival motor neuron improves neuromuscular function and motor neuron survival in mutant SOD1 mice. Neurobiol Aging. 2014; 35(4): 906-915.
3. Turner, B. J., Parkinson, N. J., Davies, K. E., and Talbot, K. Survival motor neuron deficiency enhances progression in an amyotrophic lateral sclerosis mouse model. Neurobiology of Disease. 2009; 34(3): 511-517.
4. Kariya, S., Re, D. B., Jacquier, A., Nelson, K., Przedborski, S., and Monani, U. R. Mutant superoxide dismutase 1 (SOD1), a cause of amyotrophic lateral sclerosis, disrupts the recruitment of SMN, the spinal muscular atrophy protein to nuclear Cajal bodies. Hum Mol Genet. 2012; 21(15): 3421-3434.
5. Eschbach, J., Schwalenstocker, B., Soyal, S. M., Bayer, H., Wiesner, D., Akimoto, C., Nilsson, A.-C., Birve, A., Meyer, T., Dupuis, L., Danzer, K. M., Andersen, P. M., Witting, A., Ludolph, A. C., Patsch, W., and Weydt, P. PGC-1alpha is a male-specific disease modifier of human and experimental amyotrophic lateral sclerosis. Human Molecular Genetics. 2013; 22(17): 3477-3484.
6. Weydt, P., Soyal, S. M., Landwehrmeyer, G. B., and Patsch, W. A single nucleotide polymorphism in the coding region of PGC-1alpha is a male-specific modifier of Huntington disease age-at-onset in a large European cohort. BMC Neurol. 2014; 14: 1.
7. Emery, A. E. Population frequencies of inherited neuromuscular diseases–a world survey. Neuromuscul Disord. 1991; 1(1): 19-29.
8. Larkindale, J., Yang, W., Hogan, P. F., Simon, C. J., Zhang, Y., Jain, A., Habeeb-Louks, E. M., Kennedy, A., and Cwik, V. A. Cost of illness for neuromuscular diseases in the United States. Muscle & Nerve. 2014; 49(3): 431-438.
9. Bello, L., Piva, L., Barp, A., Taglia, A., Picillo, E., Vasco, G., Pane, M., Previtali, S. C., Torrente, Y., Gazzerro, E., Motta, M. C., Grieco, G. S., Napolitano, S., Magri, F., D’Amico, A., Astrea, G., Messina, S., Sframeli, M., Vita, G. L., Boffi, P., Mongini, T., Ferlini, A., Gualandi, F., Soraru, G., Ermani, M., Vita, G., Battini, R., Bertini, E., Comi, G. P., Berardinelli, A., Minetti, C., Bruno, C., Mercuri, E., Politano, L., Angelini, C., Hoffman, E. P., and Pegoraro, E. Importance of SPP1 genotype as a covariate in clinical trials in Duchenne muscular dystrophy. Neurology. 2012; 79(2): 159-162.
10. Sleigh, J. N., Barreiro-Iglesias, A., Oliver, P. L., Biba, A., Becker, T., Davies, K. E., Becker, C. G., and Talbot, K. Chon-drolectin affects cell survival and neuronal outgrowth in in vitro and in vivo models of spinal muscular atrophy. Hum Mol Genet. 2014; 23(4): 855-869.
11. Giess, R., Holtmann, B., Braga, M., Grimm, T., Muller-Myhsok, B., Toyka, K. V., and Sendtner, M. Early onset of severe familial amyotrophic lateral sclerosis with a SOD-1 mutation: Potential impact of CNTF as a candidate modifier gene. Am J Hum Genet. 2002; 70(5): 1277-1286.
12. Pegoraro, E., Hoffman, E. P., Piva, L., Gavassini, B. F., Cagnin, S., Ermani, M., Bello, L., Soraru, G., Pacchioni, B., Bonifati, M. D., Lanfranchi, G., Angelini, C., Kesari, A., Lee, I., Gordish-Dressman, H., Devaney, J. M., and McDonald, C. M. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology. 2011; 76(3): 219-226.
13. Chang, H. C., Dimlich, D. N., Yokokura, T., Mukherjee, A., Kankel, M. W., Sen, A., Sridhar, V., Fulga, T. A., Hart, A. C., Van Vactor, D., and Artavanis-Tsakonas, S. Modeling spinal muscular atrophy in Drosophila. PLoS One. 2008; 3(9): e3209.
14. Dimitriadi, M., Sleigh, J. N., Walker, A., Chang, H. C., Sen, A., Kalloo, G., Harris, J., Barsby, T., Walsh, M. B., Satterlee, J. S., Li, C., Van Vactor, D., Artavanis-Tsakonas, S., and Hart, A. C. Conserved genes act as modifiers of invertebrate SMN loss of function defects. PLoS Genet. 2010; 6(10): e1001172.
15. Oprea, G. E., Krober, S., McWhorter, M. L., Rossoll, W., Muller, S., Krawczak, M., Bassell, G. J., Beattie, C. E., and Wirth, B. Plastin 3 is a protective modifier of autosomal recessive spinal muscular atrophy. Science. 2008; 320(5875): 524-527.
16. Granger, B., Gueneau, L., Drouin-Garraud, V., Pedergnana, V., Gagnon, F., Ben Yaou, R., Tezenas du Montcel, S., and Bonne, G. Modifier locus of the skeletal muscle involvement in Emery-Dreifuss muscular dystrophy. Hum Genet. 2011; 129(2): 149-159.
17. Esteller, M. Non-coding RNAs in human disease. Nat Rev Genet. 2011; 12(12): 861-874.
18. Berardi, E., Annibali, D., Cassano, M., Crippa, S., and Sam-paolesi, M. Molecular and cell-based therapies for muscle degenerations: A road under construction. Front Physiol. 2014; 5:119.
19. Kucherenko, M. M., Pantoja, M., Yatsenko, A. S., Shcherbata, H. R., Fischer, K. A., Maksymiv, D. V., Chernyk, Y. I., and Ruohola-Baker, H. Genetic modifier screens reveal new components that interact with the Drosophila dystroglycan-dystrophin complex. PLoS One. 2008; 3(6): e2418.
20. Li, D. K., Tisdale, S., Espinoza-Derout, J., Saieva, L., Lotti, F., and Pellizzoni, L. A cell system for phenotypic screening of modifiers of SMN2 gene expression and function. PLoS One. 2013; 8(8): e71965.
21. Vetrone, S. A., Montecino-Rodriguez, E., Kudryashova, E., Kramerova, I., Hoffman, E. P., Liu, S. D., Miceli, M. C., and Spencer, M. J. Osteopontin promotes fibrosis in dystrophic mouse muscle by modulating immune cell subsets and intramuscular TGF-beta. J Clin Invest. 2009; 119(6): 1583-1594.
22. Turk, R., Sterrenburg, E., van der Wees, C. G., de Meijer, E. J., de Menezes, R. X., Groh, S., Campbell, K. P., Noguchi, S., van Ommen, G. J., den Dunnen, J. T., and t Hoen P. A. Common pathological mechanisms in mouse models for muscular dystrophies. FASEB J. 2006; 20(1): 127-129.
23. Giacopelli, F., Marciano, R., Pistorio, A., Catarsi, P., Canini, S., Karsenty, G., and Ravazzolo, R. Polymorphisms in the osteopontin promoter affect its transcriptional activity. Physiol Genomics. 2004; 20(1): 87-96.
24. Piva, L., Gavassini, B. F., Bello, L., Fanin, M., Soraru, G., Barp, A., Ermani, M., Angelini, C., Hoffman, E. P., and Pegoraro, E. TGFBR2 but not SPP1 genotype modulates osteopontin expression in Duchenne muscular dystrophy muscle. J Pathol. 2012; 228(2): 251-259.
25. Craig, A. M., and Denhardt, D. T. The murine gene encoding secreted phosphoprotein 1 (osteopontin): Promoter structure, activity, and induction in vivo by estrogen and progesterone. Gene. 1991; 100: 163-171.
26. Arjomandi, M., Galanter, J. M., Choudhry, S., Eng, C., Hu, D., Beckman, K., Chapela, R., Rodriguez-Santana, J. R., Rodriguez-Cintron, W., Ford, J., Avila, P. C., and Burchard, E. G. Polymorphism in osteopontin gene (SPP1) is associated with asthma and related phenotypes in a puerto rican population. Pediatr Allergy Immunol Pulmonol. 2011; 24(4): 207-214.
27. Forton, A. C., Petri, M. A., Goldman, D., and Sullivan, K. E. An osteopontin (SPP1) polymorphism is associated with systemic lupus erythematosus. Hum Mutat. 2002; 19(4): 459.
28. Gazal, S., Sacre, K., Allanore, Y., Teruel, M., Goodall, A. H., Tohma, S., Alfredsson, L., Okada, Y., Xie, G., Constantin, A., Balsa, A., Kawasaki, A., Nicaise, P., Amos, C., Rodriguez-Rodriguez, L., Chioccia, G., Boileau, C., Zhang, J., Vittecoq, O., Barnetche, T., Gonzalez Gay, M. A., Furukawa, H., Can-tagrel, A., Le Loet, X., Sumida, T., Hurtado-Nedelec, M., Richez, C., Chollet-Martin, S., Schaeverbeke, T., Combe, B., Khoryati, L., Coustet, B., El-Benna, J., Siminovitch, K., Plenge, R., Padyukov, L., Martin, J., Tsuchiya, N., and Dieude, P. Identification of secreted phosphoprotein 1 gene as a new rheumatoid arthritis susceptibility gene. Ann Rheum Dis. 2014, in press.
29. Hendig, D., Arndt, M., Szliska, C., Kleesiek, K., and Got-ting, C. SPP1 promoter polymorphisms: Identification of the first modifier gene for pseudoxanthoma elasticum. Clin Chem. 2007; 53(5): 829-836.
30. Marciano, R., D’Annunzio, G., Minuto, N., Pasquali, L., Santamaria, A., Di Duca, M., Ravazzolo, R., and Lorini, R. Association of alleles at polymorphic sites in the Osteopontin encoding gene in young type 1 diabetic patients. Clin Immunol. 2009; 131(1): 84-91.
31. Niino, M., Kikuchi, S., Fukazawa, T., Yabe, I., and Tashiro, K. Genetic polymorphisms of osteopontin in association with multiple sclerosis in Japanese patients. J Neuroimmunol. 2003; 136(1-2): 125-129.
32. Uaesoontrachoon, K., Yoo, H. J., Tudor, E. M., Pike, R. N., Mackie, E. J., and Pagel, C. N. Osteopontin and skeletal muscle myoblasts: Association with muscle regeneration and regulation of myoblast function in vitro. Int J Biochem Cell Biol. 2008; 40(10): 2303-2314.
33. Hoffman, E. P., Gordish-Dressman, H., McLane, V. D., Devaney, J. M., Thompson, P. D., Visich, P., Gordon, P. M., Pescatello, L. S., Zoeller, R. F,. Moyna, N. M., Angelopoulos, T. J., Pegoraro, E., Cox, G. A., and Clarkson, P. M. Alterations in osteopontin modify muscle size in females in both humans and mice. Med Sci Sports Exerc. 2013; 45(6): 1060-1068.
34. Hullinger, T. G., Pan, Q., Viswanathan, H. L., and Somerman, M. J. TGFbeta and BMP-2 activation of the OPN promoter: Roles of smad- and hox-binding elements. Exp Cell Res. 2001; 262(1): 69-74.
35. Han, S., Guthridge, J. M., Harley, I. T., Sestak, A. L., Kim-Howard, X., Kaufman, K. M., Namjou, B., Deshmukh, H., Bruner, G., Espinoza, L. R., Gilkeson, G. S., Harley, J. B., James, J. A., and Nath, S. K. Osteopontin and systemic lupus erythematosus association: A probable gene-gender interaction. PLoS One. 2008; 3(3): e0001757.
36. Heydemann, A., Ceco, E., Lim, J. E., Hadhazy, M., Ryder, P., Moran, J. L., Beier, D. R., Palmer, A. A., and McNally, E. M. Latent TGF-beta-binding protein 4 modifies muscular dystrophy in mice. J Clin Invest. 2009; 119(12): 3703-3712.
37. Heydemann, A., Huber, J. M., Demonbreun, A., Hadhazy, M., and McNally, E. M. Genetic background influences muscular dystrophy. Neuromuscul Disord. 2005; 15(9-10): 601-609.
38. Straub, V., Rafael, J. A., Chamberlain, J. S., and Campbell, K. P. Animal models for muscular dystrophy show different patterns of sarcolemmal disruption. J Cell Biol. 1997; 139(2): 375-385.
39. Flanigan, K. M., Ceco, E., Lamar, K. M., Kaminoh, Y., Dunn, D. M., Mendell, J. R., King, W. M., Pestronk, A., Florence, J. M., Mathews, K. D., Finkel, R. S., Swoboda, K. J., Gappmaier, E., Howard, M. T., Day, J. W., McDonald, C., McNally, E. M., and Weiss, R. B. LTBP4 genotype predicts age of ambulatory loss in duchenne muscular dystrophy. Ann Neurol. 2013; 73(4): 481-488.
40. Bernasconi, P., Di Blasi, C., Mora, M., Morandi, L., Gal-biati, S., Confalonieri, P., Cornelio, F., and Mantegazza, R. Transforming growth factor-beta1 and fibrosis in congenital muscular dystrophies. Neuromuscul Disord. 1999; 9(1): 28-33.
41. Onofre-Oliveira, P. C., Santos, A. L., Martins, P. M., Ayub-Guerrieri, D., and Vainzof, M. Differential expression of genes involved in the degeneration and regeneration pathways in mouse models for muscular dystrophies. Neuromolecular Med. 2012; 14(1): 74-83.
42. Branton, M. H., and Kopp, J. B. TGF-beta and fibrosis. Microbes Infect. 1999; 1(15): 1349-1365.
43. Hersh, C. P., Demeo, D. L., Lazarus, R., Celedon, J. C., Raby, B. A., Benditt, J. O., Criner, G., Make, B., Martinez, F. J., Scanlon, P. D., Sciurba, F. C., Utz, J. P., Reilly, J. J., and Silverman, E. K. Genetic association analysis of functional impairment in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 173(9): 977-984.
44. Forsti, A., Li, X., Wagner, K., Tavelin, B., Enquist, K., Palmqvist, R., Altieri, A., Hallmans, G., Hemminki, K., and Lenner, P. Polymorphisms in the transforming growth factor beta 1 pathway in relation to colorectal cancer progression. Genes Chromosomes Cancer. 2010; 49(3): 270-281.
45. Thompson, A. R., Cooper, J. A., Jones, G. T., Drenos, F., van Bockxmeer, F. M., Biros, E., Walker, P. J., van Rij, A. M., Golledge, J., Norman, P. E., Hafez, H., and Humphries, S. E. Assessment of the association between genetic polymorphisms in transforming growth factor beta, and its binding protein (LTBP), and the presence, and expansion, of Abdominal Aortic Aneurysm. Atherosclerosis. 2010; 209(2): 367-373.
46. Swaggart, K. A., Demonbreun, A. R., Vo, A. H., Swanson, K. E., Kim, E. Y., Fahrenbach, J. P., Holley-Cuthrell, J., Eskin, A., Chen, Z., Squire, K., Heydemann, A., Palmer, A. A., Nelson, S. F., and McNally, E. M. Annexin A6 modifies muscular dystrophy by mediating sarcolemmal repair. Proc Natl Acad Sci U S A. 2014; 111(16): 6004-6009.
47. Camors, E., Monceau, V., and Charlemagne, D. Annexins and Ca2+ handling in the heart. Cardiovasc Res. 2005; 65(4): 793-802.
48. Lennon, N. J., Kho, A., Bacskai, B. J., Perlmutter, S. L., Hyman, B. T., and Brown, R. H., Jr. Dysferlin interacts with annexins A1 and A2 and mediates sarcolemmal wound-healing. J Biol Chem. 2003; 278(50): 50466-50473.
49. Cagliani, R., Magri, F., Toscano, A., Merlini, L., Fortunato, F., Lamperti, C., Rodolico, C., Prelle, A., Sironi, M., Aguennouz, M., Ciscato, P., Uncini, A., Moggio, M., Bresolin, N., and Comi, G. P. Mutation finding in patients with dysferlin deficiency and role of the dysferlin interacting proteins annexin A1 and A2 in muscular dystrophies. Hum Mutat. 2005; 26(3): 283.
50. Babiychuk, E. B., and Draeger, A. Annexins in Cell Membrane Dynamics: Ca2+-Regulated Association of Lipid Microdomains. The Journal of Cell Biology. 2000; 150(5): 1113-1124.
51. Draeger, A., Monastyrskaya, K., Burkhard, F. C., Wobus, A. M., Moss, S. E., and Babiychuk, E. B. Membrane segregation and downregulation of raft markers during sarcolemmal differentiation in skeletal muscle cells. Developmental Biology. 2003; 262(2): 324-334.
52. Roostalu, U., and Strahle, U. In vivo imaging of molecular interactions at damaged sarcolemma. Dev Cell. 2012; 22(3): 515-529.
53. He, J., Zhang, Q. J., Lin, Q. F., Chen, Y. F., Lin, X. Z., Lin, M. T., Murong, S. X., Wang, N., and Chen, W. J. Molecular analysis of SMN1, SMN2, NAIP, GTF2H2, and H4F5 genes in 157 Chinese patients with spinal muscular atrophy. Gene. 2013; 518(2): 325-329.
54. Lefebvre, S., Burglen, L., Reboullet, S., Clermont, O., Burlet, P., Viollet, L., Benichou, B., Cruaud, C., Millasseau, P., Zeviani, M., et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995; 80(1): 155-165.
55. Cobben, J. M., van der Steege, G., Grootscholten, P., de Visser, M., Scheffer, H., Buys, C. H. Deletions of the survival motor neuron gene in unaffected siblings of patients with spinal muscular atrophy. Am J Hum Genet. 1995; 57(4): 805-808.
56. Hahnen, E., Forkert, R., Marke, C., Rudnik-Schoneborn, S., Schonling, J., Zerres, K., and Wirth, B. Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: Evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet. 1995; 4(10): 1927-1933.
57. Bussaglia, E., Clermont, O., Tizzano, E., Lefebvre, S., Burglen, L., Cruaud, C., Urtizberea, J. A., Colomer, J., Munnich, A., Baiget, M., et al. A frame-shift deletion in the survival motor neuron gene in Spanish spinal muscular atrophy patients. Nat Genet. 1995; 11(3): 335-337.
58. Brahe, C., Clermont, O., Zappata, S., Tiziano, F., Melki, J., and Neri, G. Frameshift mutation in the survival motor neuron gene in a severe case of SMA type I. Hum Mol Genet. 1996; 5(12): 1971-1976.
59. Dubowitz, V. Chaos in classification of the spinal muscular atrophiesofchildhood.NeuromuscularDisorders.1991;1(2):77-80.
60. Dubowitz, V. Chaos in the classification of SMA: A possible resolution. Neuromuscular Disorders. 1995; 5(1): 3-5.
61. Russman, B. S. Spinal muscular atrophy: Clinical classification and disease heterogeneity. J Child Neurol. 2007; 22(8): 946-951.
62. Mailman, M. D., Heinz, J. W., Papp, A. C., Snyder, P. J., Sedra, M. S., Wirth, B., Burghes, A. H., and Prior, T. W. Molecular analysis of spinal muscular atrophy and modification of the phenotype by SMN2. Genet Med. 2002; 4(1): 20-26.
63. Burghes, A. H. M. When is a deletion not a deletion? When it is converted. The American Journal of Human Genetics. 1997; 61(1): 9-15.
64. Feldkotter, M., Schwarzer, V., Wirth, R., Wienker, T. F., and Wirth, B. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: Fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy. Am J Hum Genet. 2002; 70(2): 358-368.
65. Harada, Y., Sutomo, R., Sadewa, A. H., Akutsu, T., Takeshima, Y., Wada, H., Matsuo, M., and Nishio, H. Correlation between SMN2 copy number and clinical phenotype of spinal muscular atrophy: Three SMN2 copies fail to rescue some patients from the disease severity. J Neurol. 2002; 249(9): 1211-1219.
66. Wirth, B., Brichta, L., Schrank, B., Lochmuller, H., Blick, S., Baasner, A., Heller, R. Mildly affected patients with spinal muscular atrophy are partially protected by an increased SMN2 copy number. Hum Genet. 2006; 119(4): 422-428.
67. Lorson, C. L., and Androphy, E. J. An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet. 2000; 9(2): 259-265.
68. Lorson, C. L., Strasswimmer, J., Yao, J. M., Baleja, J. D., Hahnen, E., Wirth, B., Le, T., Burghes, A. H., and Androphy, E. J. SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet. 1998; 19(1): 63-66.
69. Monani, U. R., Sendtner, M., Coovert, D. D., Parsons, D. W., Andreassi, C., Le, T. T., Jablonka, S., Schrank, B., Rossoll, W., Prior, T. W., Morris, G. E., and Burghes, A. H. The human centromeric survival motor neuron gene (SMN2) rescues embryonic lethality in Smn(-/-) mice and results in a mouse with spinal muscular atrophy. Hum Mol Genet. 2000; 9(3): 333-339.
70. Andreassi, C., Angelozzi, C., Tiziano, F. D., Vitali, T., De Vincenzi, E., Boninsegna, A., Villanova, M., Bertini, E., Pini, A., Neri, G., and Brahe, C. Phenylbutyrate increases SMN expression in vitro: Relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2004; 12(1): 59-65.
71. Brahe, C., Vitali, T., Tiziano, F. D., Angelozzi, C., Pinto, A. M., Borgo, F., Moscato, U., Bertini, E., Mercuri, E., and Neri, G. Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet. 2005; 13(2): 256-259.
72. Mercuri, E., Bertini, E., Messina, S., Pelliccioni, M., D’Amico, A., Colitto, F., Mirabella, M., Tiziano, F. D., Vitali, T., Angelozzi, C., Kinali, M., Main, M., and Brahe, C. Pilot trial of phenylbutyrate in spinal muscular atrophy. Neuromuscul Disord. 2004; 14(2): 130-135.
73. Brichta, L., Holker, I., Haug, K., Klockgether, T., and Wirth, B. In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol. 2006; 59(6): 970-975.
74. Swoboda, K. J., Scott, C. B., Reyna, S. P., Prior, T. W., LaSalle, B., Sorenson, S. L., Wood, J., Acsadi, G., Crawford, T. O., Kissel, J. T., Krosschell, K. J., D’Anjou, G., Bromberg, M. B., Schroth, M. K., Chan, G. M., Elsheikh, B., and Simard, L. R. Phase II open label study of valproic acid in spinal muscular atrophy. PLoS One. 2009; 4(5): e5268.
75. Riessland, M., Ackermann, B., Forster, A., Jakubik, M., Hauke, J., Garbes, L., Fritzsche, I., Mende, Y., Blumcke, I., Hahnen, E., and Wirth, B. SAHA ameliorates the SMA phenotype in two mouse models for spinal muscular atrophy. Human Molecular Genetics. 2010; 19(8): 1492-1506.
76. Giganti, A., Plastino, J., Janji, B., Van Troys, M., Lentz, D., Ampe, C., Sykes, C., Friederich, E. Actin-filament cross-linking protein T-plastin increases Arp2/3-mediated actin-based movement. J Cell Sci. 2005; 118(Pt 6): 1255-1265.
77. Stratigopoulos, G., Lanzano, P., Deng, L., et al. ASsociation of plastin 3 expression with disease severity in spinal muscular atrophy only in postpubertal females. Archives of Neurology. 2010; 67(10): 1252-1256.
78. Ackermann, B., Krober, S., Torres-Benito, L., Borgmann, A., Peters, M., Hosseini Barkooie, S. M., Tejero, R., Jakubik, M., Schreml, J., Milbradt, J., Wunderlich, T. F., Riessland, M., Tabares, L., and Wirth, B. Plastin 3 ameliorates spinal muscular atrophy via delayed axon pruning and improves neuromuscular junction functionality. Hum Mol Genet. 2013; 22(7): 1328-1347.
79. Hao le, T., Wolman, M., Granato, M., and Beattie, C. E. Survival motor neuron affects plastin 3 protein levels leading to motor defects. J Neurosci. 2012; 32(15): 5074-5084.
80. Helmken, C., Hofmann, Y., Schoenen, F., Oprea, G., Raschke, H., Rudnik-Schoneborn, S., Zerres, K., and Wirth, B. Evidence for a modifying pathway in SMA discordant families: Reduced SMN level decreases the amount of its interacting partners and Htra2-beta1. Human Genetics. 2003; 114(1): 11-21.
81. Gangwani, L., Mikrut, M., Theroux, S., Sharma, M., and Davis, R. J. Spinal muscular atrophy disrupts the interaction of ZPR1 with the SMN protein. Nat Cell Biol. 2001; 3(4): 376-383.
82. Ahmad, S., Wang, Y., Shaik, G. M., Burghes, A. H., and Gangwani, L. The zinc finger protein ZPR1 is a potential modifier of spinal muscular atrophy. Hum Mol Genet. 2012; 21(12): 2745-2758.
83. Rosen, D. R., Sapp, P., O’Regan, J., McKenna-Yasek, D., Schlumpf, K. S., Haines, J. L., Gusella, J. F., Horvitz, H. R., and Brown, R. H., Jr. Genetic linkage analysis of familial amyotrophic lateral sclerosis using human chromosome 21 microsatellite DNA markers. Am J Med Genet. 1994; 51(1): 61-69.
84. Deng, H. X., Hentati, A., Tainer, J. A., Iqbal, Z., Cayabyab, A., Hung, W. Y., Getzoff, E. D., Hu, P., Herzfeldt, B., Roos, R. P., et al. Amyotrophic lateral sclerosis and structural defects in Cu,Zn superoxide dismutase. Science. 1993; 261(5124): 1047-1051.
85. Mancuso, R., Olivan, S., Mancera, P., Pasten-Zamorano, A., Manzano, R., Casas, C., Osta, R., and Navarro, X. Effect of genetic background on onset and disease progression in the SOD1-G93A model of amyotrophic lateral sclerosis. Amy-otroph Lateral Scler. 2012; 13(3): 302-310.
86. Kunst, C. B., Messer, L., Gordon, J., Haines, J., and Patterson, D. Genetic mapping of a mouse modifier gene that can prevent ALS onset. Genomics. 2000; 70(2): 181-189.
87. Nardo, G., Iennaco, R., Fusi, N., Heath, P. R., Marino, M., Trolese, M. C., Ferraiuolo, L., Lawrence, N., Shaw, P. J., and Bendotti, C. Transcriptomic indices of fast and slow disease progression in two mouse models of amyotrophic lateral sclerosis. Brain. 2013; 136(Pt 11): 3305-3332.
88. Riboldi, G., Nizzardo, M., Simone, C., Falcone, M., Bresolin, N., Comi, G. P., and Corti, S. ALS genetic modifiers that increase survival of SOD1 mice and are suitable for therapeutic development. Prog Neurobiol. 2011; 95(2): 133-148.
89. Klein, R. Bidirectional modulation of synaptic functions by Eph/ephrin signaling. Nat Neurosci. 2009; 12(1): 15-20.